← All trials
NCT02845986
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2016
- Primary completion
- Oct 12, 2017
- Completion date
- Oct 12, 2020
- First posted
- Jul 27, 2016
- Last posted
- Feb 5, 2020
- Enrollment
- 251
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fujian Medical UniversityLead sponsor
- Qinghai UniversityCollaborator
- Xinjiang Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Fujian Medical UniversityReponsible party - principal investigator
- Fujian Provincial HospitalCollaborator
- Guangdong Provincial Hospital of Traditional Chinese MedicineCollaborator
- Shantou UniversityCollaborator
- Longyan City First HospitalCollaborator
- Meizhou City Hospital Of Guangdong ProvienceCollaborator
- Southern Medical UniversityCollaborator
- Peking UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jilin UniversityCollaborator
- Fudan UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Xiamen UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Sichuan UniversityCollaborator
- Zhangzhou Municipal Hospital of Fujian ProvinceCollaborator
- Fujian Medical UniversityOfficial
- Putian UniversityCollaborator
- Fujian Medical UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.